Mangoceuticals has forged partnerships withโค pharmaceutical giants Eli โLilly and Novo โคNordisk to distribute their popular weight-loss drugs, the company announced Tuesday. The โagreement will allow Mangoceuticals to leverage itsโ network of pharmacies to expand access to medications like Lilly’s Zepbound โขand Novo Nordisk’s Wegovy, both in highโค demand amid a growing obesity epidemic.
The move comes as demand โfor GLP-1 receptor agonists – a class of drugsโค initially developed for diabetes that have demonstrated significant weight-loss benefits – continues to outstrip supply. Mangoceuticals aims to address accessibility challenges and provide โขa streamlined โpurchasing experience for patients and healthcare providers. Theโ partnerships representโค a significantโฃ expansion for Mangoceuticals beyondโ its conventional compounding pharmacy services and โคposition it as a key โplayer in the rapidly evolving weight-loss market.
Under the agreements, Mangoceuticals will actโฃ as a wholesale distributor, supplying Zepbound and Wegovy to a network of autonomousโ pharmacies โคacross the United states. The company anticipates beginning distributionโ in โคthe coming weeks, with โa phased rollout planned to ensure a consistent โsupply.”We are thrilled to partner with lilly and Novoโ Nordisk to bring theseโ life-changing medications to more patients,” said Mangoceuticals CEOโ Mohit kaushal in a statement. “Our extensive pharmacyโ network and commitment to customer service will help ensure that individuals have convenientโฃ access to the treatments thayโ need.”
The โคpartnerships are non-exclusive, โmeaning both Lilly and Novo Nordisk will continue to workโฃ with other distributors. However, mangoceuticals’โ focus on independent pharmacies could provide an โฃoption channelโค for patients who have struggled to obtain the drugs through traditional retail chains. โ
Demand for โคweight-loss drugs has surged in recent months, driven byโข increased awarenessโค of obesity as aโ chronic health condition and โคthe proven efficacy of GLP-1 agonists.Wegovy โand Zepbound have โbothโฃ shown remarkable results inโ clinical trials, leading to significant weight loss and improvements in relatedโค health โขmarkers.
